17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma

Inclusion Criteria:

* Negative pregnancy test
* Fertile patients must use effective contraception prior to and during study treatment
* Must have normal organ and marrow function
* Not a candidate for stem cell transplantation
* ECOG 0-2 OR Karnofsky 60-100%
* Bilirubin normal
* Creatinine normal
* Histologically or cytologically confirmed relapsed or refractory mantle cell lymphoma, anaplastic large cell lymphoma (CD30-positive disease), or classical Hodgkin's lymphoma
* Recovered from prior biologic therapy or autologous stem cell transplantation
* Prior antibody therapy within the past 3 months allowed
* More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
* More than 4 weeks since prior radiotherapy (12 weeks for radioimmunotherapy) and recovered
* Recovered from prior investigational drugs
* Recovered from prior surgery
* More than 4 weeks since other prior anticancer therapy
* Concurrent low-molecular weight heparin is allowed
* Measurable disease, defined as \>= 1 unidimensionally measurable lesion \>= 20 mm
* Absolute neutrophil count \>= 1,500/mm3
* Received \>= 1, but =\< 3, prior treatment regimens for lymphoma (salvage therapy followed immediately by stem cell transplantation is considered 1 regimen). Single-agent monoclonal antibody therapy, cytokine therapy, or involved field radiotherapy are not considered prior treatment regimens. All prior treatments and prior antibody therapy within the past 3 months are recorded.
* Platelet count \>= 75,000/mm3
* AST and ALT =\< 1.5 times upper limit of normal
* Understand and provide signed informed consent.

Exclusion Criteria:

* No cardiac arrhythmia or uncontrolled dysrhythmia
* No history of myocardial infarction within the past year
* No New York Heart Association class III or IV heart failure
* No other significant cardiac disease
* No paroxysmal nocturnal dyspnea
* No oxygen requirement
* No AIDS
* No history cardiac toxicity after receiving anthracyclines (e.g., doxorubicin hydrochloride, daunorubcin hydrochloride, mitoxantrone, bleomycin, or carmustine)
* No pulmonary lymphoma
* No known CNS lymphoma
* QTc \>/= 450 msec for men
* QTc \>/= 470 msec for women
* LVEF \</= 40% by MUGA
* No symptomatic congestive heart failure
* No unstable angina pectoris
* No symptomatic pulmonary disease requiring medication
* No significant pulmonary disease including chronic obstructive or restrictive pulmonary disease
* No dyspnea on or off exertion
* No history of pulmonary toxicity after receiving anthracyclines (e.g., doxorubicin hydrochloride, daunorubcin hydrochloride, mitoxantrone, bleomycin, or carmustine)
* Not pregnant or nursing
* No other uncontrolled illness
* No other active\* malignancy except nonmelanoma skin cancer or carcinoma in situ of the cervix
* No prior allogeneic stem cell transplantation
* No history of allergic reaction to eggs
* No ongoing or active infection
* No psychiatric illness or social situation that would preclude study compliance
* No prior chest radiation or prior radiation that potentially included the heart in the field (e.g.,mantle).
* No concurrent medications that prolong or may prolong QTc
* No concurrent combination antiretroviral therapy for HIV-positive patients
* No other concurrent investigational agents
* No other concurrent anticancer therapy
* No prior cardiac symptoms \>= grade 2
* No sufficiently compromised pulmonary status (i.e., DLCO =\< 80%)
* No history of serious ventricular arrhythmia (e.g., ventricular tachycardia or ventricular fibrillation \>= 3 beats in a row)
* No prior pulmonary symptoms \>= grade 2
* HIV negative
* No active ischemic heart disease within 12 months.
* No congenital long QT syndrome.
* No left bundle branch block.